Overview Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Status: Withdrawn Trial end date: 2020-12-01 Target enrollment: Participant gender: Summary This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase. Phase: Phase 1/Phase 2 Details Lead Sponsor: NeuroVia, Inc.